Bionano Genomics (Bionano Genomics) Gross Margin % : 32.20% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Bionano Genomics's Gross Profit for the three months ended in Mar. 2024 was $2.82 Mil. Bionano Genomics's Revenue for the three months ended in Mar. 2024 was $8.77 Mil. Therefore, Bionano Genomics's Gross Margin % for the quarter that ended in Mar. 2024 was 32.20%.

Warning Sign:

Bionano Genomics Inc gross margin has been in long-term decline. The average rate of decline per year is -5.3%.

The historical rank and industry rank for Bionano Genomics's Gross Margin % or its related term are showing as below:

BNGO' s Gross Margin % Range Over the Past 10 Years
Min: 21.38 Med: 30.01 Max: 47.31
Current: 27.54

During the past 8 years, the highest Gross Margin % of Bionano Genomics was 47.31%. The lowest was 21.38%. And the median was 30.01%.

BNGO's Gross Margin % is ranked worse than
81.45% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 52.94 vs BNGO: 27.54

Bionano Genomics had a gross margin of 32.20% for the quarter that ended in Mar. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Bionano Genomics was -5.30% per year.

Bionano Genomics Gross Margin % Historical Data

The historical data trend for Bionano Genomics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Gross Margin % Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

33.18

32.61

21.54

21.38

26.49

Bionano Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial															27.92	26.65	29.50	22.74	32.20

Competitive Comparison of Bionano Genomics's Gross Margin %

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Gross Margin % falls into.

Bionano Genomics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bionano Genomics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	9.6	/	36.116
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(36.116 - 26.55)	/	36.116
	=	26.49 %

Bionano Genomics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	2.8	/	8.769
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(8.769 - 5.945)	/	8.769
	=	32.20 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Bionano Genomics (NAS:BNGO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bionano Genomics had a gross margin of 32.20% for the quarter that ended in Mar. 2024 => Competition eroding margins

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Bionano Genomics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics (Bionano Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

BNGO:Mexico

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.

Executives

Gulsen Kama	officer: Chief Financial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin	director, officer: President and CEO	4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart	officer: Chief Financial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon	officer: General Counsel	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic	director	9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong	director	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams	officer: Chief Informatics Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy	officer: Chief Business Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar	officer: Chief Commercial Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey	officer: Chief Medical Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams	officer: Chief Administrative Officer	C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011